80 Quick summary: A Westminster Hall debate sparked by a petition with over 106,000 signatures has intensified pressure on the United Kingdom government to lower the routine breast screening age from 50 to 40. While parliamentarians from across parties supported the expansion to catch aggressive cancers earlier in younger women, public health officials are delaying immediate policy changes until conclusive results from the AgeX clinical trial emerge later in 2026. For public policy and healthcare practice, campaigners argue that immediate interventions are still required to widen screening access in deprived communities, tackle health inequalities, and accelerate alternative diagnostic techniques to save lives and improve long-term well-being. A Westminster Hall debate held on Monday (29th June) brought renewed focus to whether routine breast screening in the UK should begin at age 40 rather than 50, following a petition signed by more than 106,000 people. The petition was launched by Gemma Reeves, a chemotherapy nurse, and surpassed 100,000 signatures, triggering parliamentary consideration. Despite cross-party backing from MPs, no immediate change to the screening age was agreed. Cancer charity Walk the Walk has made expanding access to breast screening a key campaigning priority and has actively supported the petition. Earlier this year, the charity hosted a parliamentary drop-in event on World Cancer Day, calling for the routine screening age to be widened below 50 and above 70, improved cancer prevention education, and greater focus on physical activity, including walking, in cancer prevention and recovery. Commenting on the debate, Nina Barough CBE, founder of Walk the Walk, said: “Following the debate in Parliament, it was clear there is broad agreement across MPs on the need to lower the age for breast screening, and we welcome that shared commitment. However, while we recognise the Government’s position on waiting for further evidence before lowering the age at which women are called for screening from the AgeX trial, we believe there are steps that can and must be taken now. In particular, widening access to screening in deprived communities and addressing inequalities in uptake cannot wait. We are also encouraged to hear growing recognition of the challenges younger women face, especially around denser breast tissue, and we urge the Government to accelerate work on alternative diagnostic techniques. Every delay risks lives, and we believe more can be done now to ensure earlier diagnosis and better outcomes for thousands of women.” The NHS Breast Screening Programme currently invites women aged 50–70 for mammograms every three years. Breast cancer remains one of the most common cancers in the UK, with thousands of cases diagnosed outside this age range annually. Campaigners argue that earlier detection through screening starting at 40 could lead to better survival rates, particularly for younger women who may face more aggressive forms of the disease or denser breast tissue that can make detection harder with standard mammography. During the debate, MPs highlighted stories of women diagnosed with breast cancer in their 40s, often after noticing symptoms themselves rather than through routine screening. Supporters of the petition, including cross-party voices, emphasised the potential to save lives by catching cancers at an earlier, more treatable stage. The AgeX trial, run by researchers including teams at the University of Oxford, is examining the benefits and harms of extending screening invitations to women aged 47–49 and 71–73. Early results from aspects of the trial are anticipated later in 2026, which the Government has cited as a key reason for caution on immediate policy changes. The Government has indicated it will continue to monitor evidence from trials such as AgeX before making significant alterations to the national programme. Concerns were also raised during the debate about the capacity of the NHS to handle increased demand, potential overdiagnosis, and the need for robust evidence before any expansion goes ahead. Addressing uptake in deprived areas is seen as a priority, since lower participation rates in certain communities contribute to later-stage diagnoses and poorer prognosis. Reeves, drawing on her frontline experience as a chemotherapy nurse, has called not only for lowering the starting age to 40 but also for more frequent annual invitations. Walk the Walk, known for its fundraising MoonWalk events, has long championed research, prevention, and support for those affected by breast cancer, and its involvement has helped keep the issue prominent in parliamentary circles. Lauren and David from Walk the Walk were pictured with Reeves at the debate, symbolising the collaborative effort behind the campaign. Health experts note that while screening programmes have contributed to improved outcomes since their introduction, evolving demographics, advances in technology, and greater awareness of inequalities mean the programme requires ongoing review. While the debate did not yield immediate policy shifts, it has sustained political pressure and public discussion around the issue, reflecting broader momentum behind preventive health measures and earlier cancer detection strategies in the UK.